
Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the…
The integration of BSV is on track, with focus on mandate brands, improving productivity and adopting best practices to ensure…
The Hyderabad-based drug major had reported a profit of Rs 1,379 crore for the October-December period of last fiscal. Revenue…
Patients should stop taking glatiramer acetate and seek immediate medical attention by going to an emergency room or calling 911…
India faces a rising burden of blood cancers, with around 120,000 new cases and over 70,000 deaths annually from leukemia,…
To make cancer care more affordable in price-sensitive India, Mazumdar-Shaw said, the government must also cut import duties for high-tech…
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for 50% of the company’s…
The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition in atopic dermatitis treatment.
The risk to the general public from bird flu is low, and there has been no further evidence of person…
Indian pharma set for shake-up with entry of these drugs.
“With the objective of optimizing resources and ensuring long-term operational sustainability, some roles have become redundant,” says the company spokesperson
The therapy is a critical treatment option for various life-threatening disease. Earlier, GST on gene therapy was set at 12…
Budget 2025: Saransh Chaudhary, President, Global Critical Care, Venus Remedies Ltd and CEO, Venus Medicine Research Centre said that they…
Recently in 2024, the agency received a report involving a patient who received the nasal solution as an injection.
On December 13, 2024, Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announced a license agreement for evenamide…
Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax SM) had an estimated annual sale of USD 36 million in the U.S.…
China’s drug regulator granted approval for the vaccine to now be used for males aged 9-26 years.
Novartis plans to share STEER results with regulatory agencies including the FDA in 2025.